A randomised, placebo-controlled, double blind study of treatment of Huntington’s disease with unsaturated fatty acids

Vaddadi, Krishna S; Soosai, E.; Chiu, Edmond; Dingjan, Phillip

doi:10.1097/00001756-200201210-00011

Cited by 65 publications

(34 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An open label study with EPA in Huntington's disease patients showed significant improvements in motor function compared to the placebo group (Vaddadi et al 2002). A pilot study with EPA was carried out in patients with advanced (stage III) Huntington's disease.…”

Section: Huntington's Diseasementioning

confidence: 99%

Neurological Benefits of Omega-3 Fatty Acids

2008

View full text Add to dashboard Cite

The central nervous system is highly enriched in long-chain polyunsaturated fatty acid (PUFA) of the omega-6 and omega-3 series. The presence of these fatty acids as structural components of neuronal membranes influences cellular function both directly, through effects on membrane properties, and also by acting as a precursor pool for lipid-derived messengers. An adequate intake of omega-3 PUFA is essential for optimal visual function and neural development. Furthermore, there is increasing evidence that increased intake of the long-chain omega-3 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may confer benefits in a variety of psychiatric and neurological disorders, and in particular neurodegenerative conditions. However, the mechanisms underlying these beneficial effects are still poorly understood. Recent evidence also indicates that in addition to the positive effects seen in chronic neurodegenerative conditions, omega-3 PUFA may also have significant neuroprotective potential in acute neurological injury. Thus, these compounds offer an intriguing prospect as potentially new therapeutic approaches in both chronic and acute conditions. The purpose of this article is to review the current evidence of the neurological benefits of omega-3 PUFA, looking specifically at neurodegenerative conditions and acute neurological injury.

show abstract

Section: Huntington's Diseasementioning

confidence: 99%

Neurological Benefits of Omega-3 Fatty Acids

2008

View full text Add to dashboard Cite

show abstract

“…The patients have been reported to exhibit improvements in motor and cognitive performance after treatment. 133,134 …”

Section: Therapeutic Treatments Targeting Energy Metabolism and Dietmentioning

confidence: 99%

The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

2005

View full text Add to dashboard Cite

Summary:Huntington's disease (HD) is a genetic neurodegenerative disorder. Since identification of the disease-causing gene in 1993, a number of genetically modified animal models of HD have been generated. The first transgenic mouse models, R6/1 and R6/2 lines, were established 8 years ago. The R6/2 mice have been the best characterized and the most widely used model to study pathogenesis of HD and therapeutic interventions. In the present review, we especially focus on the characteristics of R6 transgenic mouse models and, in greater detail, describe the different therapeutic strategies that have been tested in these mice. We also, at the end, critically assess the relevance of the HD mouse models compared with the human disease and discuss how they can be best used in the future.

show abstract

“…Controlled clinical trials indicate that omega-3 fatty acids may be beneficial either as sole or an augmentation treatment in a range of neuropsychiatric conditions with conflicting results (Schachter et al, 2005). Controlled trails in individuals with childhood disorders such as dyslexia or attention deficit and hyperactivity disorders (Richardson & Montgomery, 2005), major depression (Su, Huang, Chiu, & Shen, 2003;Nemets, Stahl, & Belmaker, 2002;Peet & Horrobin, 2002;Puri, Counsell, Richardson, & Horrobin, 2002b), bipolar disorder (Stoll et al, 1999), borderline personality disorder (Zanarini & Frankenburg, 2003), and incarcerated young males (Gesch, Hammond, Hampson, Eves, & Crowder, 2002) suggest that omega-3 fatty acids may modulate mood, impulsivity and aggression, while more robust effects have been associated with the treatment of movement abnormalities in Huntington's disease (Vaddadi, Soosai, Chiu, & Dingjan, 2002;Clifford et al, 2002;Puri, et al, 2002a;Puri et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

Bioactive lipids in schizophrenia

Berger

Smesny

Amminger

2006

International Review of Psychiatry

View full text Add to dashboard Cite

SummaryBioactive lipids, in particular arachidonic acid (AA), are vital for monoaminergic neurotransmission, brain development and synaptic plasticity. Phospholipases A2 (PLA2) are key-enzymes in AA metabolism and are activated during monoaminergic neurotransmission. Reduced membrane AA levels, and an altered activity of PLA2 have been found in peripheral membranes of drug-naïve patients with schizophrenia with some conflicting results in more chronic patient populations. Furthermore, in vivo brain phosphorus-31 magnetic resonance spectroscopy suggests reduced lipid membrane precursors (phosphomonoesters) and increased membrane breakdown products (phosphodiesters) in drug-naïve or early treated firstepisode schizophrenia patients compared to age-matched controls or chronic populations and these changes were correlated with peripheral red blood cell membrane AA levels. We postulate that processes modulating membrane lipid metabolism are associated with psychotic illnesses and might partially explain the mechanism of action of antipsychotic agents, as well as experimental agents such as purified ethyl-eicosapentaenoic acid (E-EPA). Recent supplementation trials suggest that E-EPA is a modestly effective augmentation treatment resulting in reduced doses of antipsychotic medication in acutely ill patients with schizophrenia (but not in residual-type schizophrenia). This review investigates the role of bioactive lipids in schizophrenia and its treatment, as well as its potential use in prevention.

show abstract

A randomised, placebo-controlled, double blind study of treatment of Huntington’s disease with unsaturated fatty acids

Cited by 65 publications

References 7 publications

Neurological Benefits of Omega-3 Fatty Acids

Neurological Benefits of Omega-3 Fatty Acids

The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

Bioactive lipids in schizophrenia

Contact Info

Product

Resources

About